05.22.26 -- Patient Trust And Engagement In The Age Of Decentralized Trials

Health Canada is tightening foreign action reporting expectations. MAHs need to understand what the updated draft guidance means for their compliance and monitoring processes now.

Modular automation is reshaping manufacturing by enabling faster changeovers, reduced downtime, and built‑in compliance. Learn how the “ballroom” approach helps teams adapt to shifting demand.

See how one family managed to get an investigational gene replacement therapy manufactured and approved by the FDA so their daughter could be dosed just 14 months from her diagnosis.

To truly maximize enrollment in decentralized models, sponsors must invest in human connection to build the trust needed to move patients from awareness to active participation.

Examine the complexities of participant payments in clinical trials with a focus on prepaid cards and other payment methods.

Learn how lentiviral vector processes evolve for in vivo and ex vivo CAR‑T—covering yield, purity, scalability, and shifting regulatory demands for safe, consistent systemic delivery.

Oxygen heterogeneity, caused by pressure variations and other factors in large-scale bioreactors, can significantly impact cell growth and product yield.

Build scalable material sourcing strategies for R&D and early phases through to commercialization and learn how to accelerate the development process and ensure the scalability of your biologics.